Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

被引：68
作者：
Cornberg M. [1 ]
Wedemeyer H. [1 ]
Manns M.P. [1 ]
机构：
[1] Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Carl-Neuberg-Strasse 1
来源：
Current Gastroenterology Reports | 2002年 / 4卷 / 1期
关键词：
Sustained Virologic Response; Sustained Virologic Response Rate; Million Unit; Sustained Response Rate; International Hepatitis Interventional Therapy Group;
D O I：
10.1007/s11894-002-0034-y
中图分类号：
学科分类号：
摘要：
Treatment with interferon alfa combined with ribavirin is successful in approximately 40% to 45% of patients with chronic hepatitis C viral infection (HCV). However, response rates are disappointing in patients who are difficult to treat, such as those infected with HCV genotype 1, high viral load, or advanced liver fibrosis. In addition, low tolerability and significant side effects of therapy frequently lead to dose reduction and treatment discontinuation, decreasing response rates further. Thus, investigation of new treatment options and innovations for chronic HCV infection are vital. This review describes recent advances in the treatment of HCV infection with PEGylated interferon (interferon modified with polyethylene glycol [PEG] ) combined with ribavirin.
引用
收藏
页码：23 / 30
页数：7
相关论文
共 74 条
[1]  
Lau DT(1998)10-Year follow-up after interferon-alpha therapy for chronic hepatitis C Hepatology 28 1121-1127
[2]  
Kleiner DE(2001)Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis Lancet 357 196-197
[3]  
Ghany MG(1995)Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1051-1055
[4]  
Nishiguchi S(2000)45-Year follow-up of hepatitis C virus infection in healthy young adults Ann Intern Med 132 105-111
[5]  
Shiomi S(2000)Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study Hepatology 32 91-96
[6]  
Nakatani S(1999)Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1228-1233
[7]  
Nishiguchi S(2001)The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection Gut 49 423-430
[8]  
Kuroki T(1998)Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1426-1432
[9]  
Nakatani S(1998)Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1485-1492
[10]  
Seeff LB(1998)Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group N Engl J Med 339 1493-1499
12345678